Objective: To evaluate the effectiveness of prophylaxis with coagulation factor concentrates VIII/IX (FVII/IX) in children with severe hemophilia A/B, respectively. Materials and Methods: Retrospective observational study was done on children enrolled in our hemophilia clinic, who initially received “on demand” therapy and were on prophylaxis with factor VIII/IX concentrate at the time of the study. The study group consisted of 8 children. Annual hemarthrosis rate (AHR) over a period of 1-year during on demand therapy was compared with AHR during a period of 1-year on prophylaxis with FVIII/IX. Results: There was reduction in AHR by 87% in hemophilia A and 85% in hemophilia B during prophylaxis compared to on demand therapy. There was a significant reduction in hemarthrosis/patient/year from 2.5 to 0.3 on prophylaxis with factor concentrate compared to on demand therapy. There was also reduction in other bleeding manifestation like psoas muscle bleed, oral bleeds, epistaxis, and number of target joints involved. Conclusion: Prophylaxis with coagulation factor concentrate significantly reduces the AHR, and hence, decreases the disability associated with it compared to “on demand” therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.